A Phase III Randomized Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of 3TC/ZDV/1592U89 and 3TC/ZDV/IDV in HIV-1 Infected Antiretroviral Therapy-Naive Subjects.

Inclusion Criteria Concurrent Medication: Allowed: GM-CSF, G-CSF, and erythropoietin. Concurrent Treatment: Allowed: Local treatment for Kaposi's sarcoma. Patients must have: * HIV-1 infection documented by a licensed HIV-1 antibody ELISA and confirmed by Western blot detection of HIV-1 antibody or positive HIV-1 blood culture. * CD4+ cell count \>= 100 cells/mm3 within 14 days prior to study drug administration. * HIV-1 RNA \>= 10,000 copies/ml within 14 days prior to study drug administration. * No active diagnosis of AIDS according to the 1993 Centers for Disease Control (CDC) AIDS surveillance definition (excluding CD4+ cell counts \< 200 cells/mm3). * Signed, informed consent from parent or legal guardian for patients under 18 years of age. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: * Malabsorption syndrome or other gastrointestinal dysfunction that may interfere with drug absorption. * Serious medical conditions such as diabetes, congestive heart failure, cardiomyopathy, or other cardiac dysfunction that would compromise the safety of the patient. Concurrent Medication: Excluded: * Cytotoxic chemotherapeutic agents. * Agents with documented anti-HIV-1 activity in vitro. * Foscarnet. * Immunomodulating agents such as systemic corticosteroids, interleukins, thalidomide, or interferons. * Terfenadine, astemizole, cisapride, triazolam, midazolam, and ergotamine/dihydroergotamine. Concurrent Trea…